Integra LifeSciences Holdings Corporation
NASDAQ:IARTMedical - Devices
+$0.81 today
- Market cap
- $1.08B
- Beta
- 1.25
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$6.44
Volume 0.58M
Average 0.96M
IART Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Integra LifeSciences Holdings CorporationNASDAQ: IART
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $23.5M fell 5.0% year over year, ahead of the -13.6% change in trailing-twelve-month research & development. Sequentially, it fell 5.2% from the prior quarter. Over 3 fiscal years it compounded at -0.7% a year.
Context
- Research & development amounted to 6.1% of revenue in FY2025, down 1.1 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -5.0% holds above the trailing-twelve-month pace of -13.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 98.97M USD
- Year-over-year change
- -14.2%
- 4-year CAGR
- +1.6%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 98.97M | -14.2% |
| FY2024 | 2024-12-31 | 115.38M | +10.7% |
| FY2023 | 2023-12-31 | 104.19M | +3.0% |
| FY2022 | 2022-12-31 | 101.19M | +8.8% |
| FY2021 | 2021-12-31 | 93.05M | — |
Research & Development vs competitors
How IART compares with its peers on the latest reported figures
- IART's LTM Mar 2026 research & development of $97.75M is the 4th highest of the 11 companies compared; the peer median is $60.34M.
- Its year-over-year change of -13.6% is the 10th highest of 11, against a peer median of +9.0%.
- Research & development amounts to 5.9% of revenue for IART, versus a peer median of 6.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.66B | +10.1% | +8.8% | 6.4% | |
| FY2025 | $346M | +0.9% | +0.1% | 5.6% | |
| LTM Jun 2026 | $184.82M | +30.3% | +36.3% | 5.9% | |
| LTM Mar 2026 | $97.75M | -13.6% | -0.7% | 5.9% | |
| LTM Mar 2026 | $77.25M | -2.6% | +20.1% | 9.8% | |
| LTM Mar 2026 | $61.4M | -16.9% | +5.2% | 7.4% | |
| LTM Mar 2026 | $59.27M | +10.2% | +5.8% | 4.3% | |
| LTM Sep 2026 | $37.43M | +37.4% | +8.7% | 14.0% | |
| LTM Mar 2026 | $33.1M | +17.2% | -7.3% | 7.2% | |
| LTM Jun 2026 | $9.54M | +8.0% | +1.0% | 11.9% | |
| LTM Mar 2026 | $2.09M | -9.0% | +31.9% | 1.7% | |
| Peer median (excluding IART) | $60.34M | +9.0% | +7.2% | 6.8% | |
Competitors are the stored peer set for IART. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.54B | 1.56B | 1.54B | 1.61B | 1.64B |
| Cost of Revenue | 597.81M | 587.36M | 656.84M | 728.47M | 790.01M |
| Gross Profit | 944.64M | 970.31M | 884.74M | 882.06M | 845.23M |
| Gross Margin | 61.2% | 62.3% | 57.4% | 54.8% | 51.7% |
| Research & Development | 93.05M | 101.19M | 104.19M | 115.38M | 98.97M |
| Selling, General & Admin | 637.45M | 616.32M | 656.64M | 716.98M | 699.7M |
| Operating Expenses | 747.41M | 731.39M | 773.21M | 853.65M | 776.92M |
| Depreciation & Amortization | 123.67M | 121.12M | 123.51M | 140.5M | 151.05M |
| EBITDA | 366.33M | 384.6M | 255.96M | 193.29M | (326.2M) |
| EBITDA Margin | 23.7% | 24.7% | 16.6% | 12.0% | -19.9% |
| Operating Income | 197.23M | 238.92M | 111.53M | 28.41M | 68.32M |
| Operating Margin | 12.8% | 15.3% | 7.2% | 1.8% | 4.2% |
| Interest Income | 6.74M | 11.92M | 17.2M | 20.04M | 18.47M |
| Interest Expense | 50.4M | 49.59M | 51.38M | 70.63M | 86.26M |
| Other Income / Expenses | 17.45M | (25.03M) | (30.46M) | (46.65M) | (631.82M) |
| Income Before Tax | 214.68M | 213.89M | 81.07M | (18.24M) | (563.5M) |
| Pre-Tax Margin | 13.9% | 13.7% | 5.3% | -1.1% | -34.5% |
| Income Tax Expense | 45.6M | 33.34M | 13.33M | (11.29M) | (47.03M) |
| Net Income | 169.08M | 180.55M | 67.74M | (6.94M) | (516.47M) |
| Net Margin | 11.0% | 11.6% | 4.4% | -0.4% | -31.6% |
| EPS (Basic) | 2.00 | 2.18 | 0.87 | (0.09) | (6.73) |
| EPS (Diluted) | 1.98 | 2.16 | 0.84 | (0.09) | (6.73) |
| Weighted Avg Shares | 84.7M | 83M | 78.17M | 77.01M | 76.75M |
| Weighted Avg Shares (Diluted) | 85.49M | 83.52M | 80.34M | 77.01M | 76.75M |
Integra LifeSciences Holdings Corporation
NASDAQ:IART
Intrinsic Alpha fair value
Locked
Current Price
$13.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.